MCBRIDE PLC (MCB) — Investment Research Note

Executive summary

McBride is Europe's leading private-label manufacturer of household cleaning and hygiene products (liquids, unit dosing tablets/capsules, powders, aerosols) sold primarily to retailers, with a smaller contract-manufacturing business for branded FMCG clients. Following a near-death cost-inflation squeeze in FY22–FY23, the group has delivered five consecutive half-years of restored profitability (adj EBITDA margin ~8.8–9.3%), reinstated dividends, refinanced its RCF to Nov-2029, launched a £20m buyback and completed the €35.6m Eurotab bolt-on to deepen its unit-dosing platform. The single most important point for valuation today is that recent Middle East–driven petrochemical cost inflation has forced a modest 5–10% cut to FY26/FY27 consensus 2026-06 trading update while the shares are still trading on a low single-digit forward EV/EBITDA — the debate is whether the pricing/lag pattern normalises again by early FY27 as management guides.

Fair value estimate

• Fair value range: 220p – 280p per share (implied market cap £374m – £475m; midpoint ~£425m)
• Methodology: EV/EBITDA multiple on FY27 pro-forma adj EBITDA, sense-checked against a forward P/E cross-read.
• Key assumptions:
  • FY26 adj EBITDA of ~£78–82m (analyst consensus adj EBITA £64.2m cut 5–10% 2026-06 trading update + ~£20m D&A).
  • FY27 pro-forma adj EBITDA of ~£95m: consensus FY27 adj EBITA £70.6m cut 5–10% → ~£64–67m, add D&A £21m, add Eurotab contribution (€65m revenue, ~15% div margin → ~£8m EBITDA) 2026-04-02 acquisition announcement.
  • EV/EBITDA multiple of 6.0–7.0x — a discount to defensive staples peers (10–13x) reflecting the commodity-processor economics and pension overhang, but a premium to trough levels.
  • Net debt bridge: current £120.6m + Eurotab consideration £30.7m already drawn under RCF, offset by ~£20m FY26 free cash flow and ~£10m buyback = ~£140m at FY27E 2026-02 interims + 2026-07 completion.
• Cross-check (P/E): Adj basic EPS FY25 22.1p 2025-09 final results; FY27E pro-forma adj EPS ~22–26p. At 10x P/E → 220–260p.
• Current market cap £307.0m vs midpoint fair value £425m → absolute upside ~+38% (range: +22% to +55%).

Sector context

• Sector: Consumer Staples / Personal Care, Drug and Grocery Stores (confirmed) — specifically private-label household cleaning products.
• Quality/growth/leverage profile: Below-typical staples on quality (low gross margin ~36%, thin EBIT margin), broadly in line on leverage (1.4x), below-typical on growth (LT target 2% revenue). Not a "compounder" — a scale, low-cost private-label supplier.
• Listed peers: Henkel (KGaA) as a branded competitor in the private-label space; Reckitt Benckiser (branded competition); PZ Cussons (UK personal care). The nearest pure private-label comps are private (e.g. Fareva, Roquette in adjacent categories); this is a niche listed pure-play.

Investment thesis

• Private label share continues to gain in a cost-of-living market: Overall market share for private-label household is at recent all-time highs for the 7th consecutive quarter, with McBride outperforming (H1 FY26 private label vols +0.9% vs market growth) 2026-02 interims. Cost-conscious consumers keep switching from brands.
• Balance sheet normalised → capital return machine has restarted: RCF extended to Nov-2029, net debt 1.4x EBITDA, £20m buyback with intention to expand to 25% of shares if undervaluation persists 2025-11 AGM update; dividend reinstated. Board explicitly calls out that market cap "fundamentally undervalues" the group 2025-11 AGM update.
• Eurotab acquisition adds capacity + margin accretion: EBITDA multiple 3.1x post-synergies, immediately EPS accretive, adds ~0.5ppt to group EBITDA margin, addresses unit-dosing capacity constraints 2026-04 acquisition; 2026-07 completion. Positions the group toward its 10% EBITDA margin target set at 2024 Capital Markets Day.

Key risks

• Raw material / geopolitical shock recurrence: The Middle East conflict has already forced a 5–10% cut to FY26/FY27 adj EBITA guidance because of petrochemical cost pass-through lags 2026-06 trading update. The FY22–FY23 collapse showed how brutal these lags can be when supply-chain shocks compound.
• Contract-manufacturing lumpiness: Contract manufacturing (~13.6% of revenue) grew 48.9% in FY25 on one big new deal 2025-09 final results; unit dosing contract volumes fell 3.7% in H1 FY26 2026-02 interims. Single-contract concentration risk is significant.
• UK defined benefit pension overhang: £23.1m recognised deficit at Dec-25 with £5.7m/year cash contributions to 2028 plus conditional profit-related top-ups 2026-02 interims. Virgin Media pension case still an unresolved contingent liability though not currently expected to add to liabilities.

Operating leverage

McBride is a medium-low operating leverage business. Cost of sales is ~63% of revenue and largely variable (raw materials, packaging, energy); direct labour and factory overheads are semi-fixed. Adjusted EBITDA margin has cycled from -0.5% (FY22) to 9.3% (FY25) — the delta was driven by pricing recovery, not volume operating leverage. Group has explicitly limited its ability to capture upside by adopting a 3-month rolling pricing mechanism that limits margin expansion in falling-cost periods (in exchange for downside protection). Divisional profit swings in FY25 vs FY22 (Liquids £45.6m from -£15.9m, Unit Dosing £22.5m from -£0.8m) reflect ~7ppt gross margin swing on similar volumes, i.e. very high price/cost sensitivity but not classic volume leverage 2025-09 final results, 2022-09 final results. A 10-20% revenue beat driven by volume would likely add ~30–50% to operating profit through fixed-cost absorption in factories (14 sites), not multiples. Contribution margins on incremental private-label volume are probably in the mid-teens gross, dropping to ~20-25% at operating level with fixed overhead absorbed. The Eurotab tuck-in adds ~0.5ppt to group EBITDA margin at scale, reinforcing that this is a manufacturing business with meaningful but not spectacular scale economics.

Value-trap signals

None identified. Consistent recent execution, dividend reinstated, active buyback, board acknowledges undervaluation, private-label demand structurally rising. The historical near-blow-up in FY22–23 was a cost-shock, not structural decline. Watch: pension overhang, customer service disruption from SAP S/4HANA rollout, and the willingness of retailers to accept price rises if input costs re-inflate.

Earnings vs expectations

Post-turnaround, the pattern has been "beat then in-line, then a fresh external cost shock." Management is now credible on the direction of travel but has just delivered the first negative preannouncement of the current cycle.

Conviction

Conviction: 3 (moderate).

Anchors: (i) clean, well-disclosed financials with clear divisional breakdown; (ii) five consecutive H1s at similar profit levels give a solid revenue/margin anchor; (iii) two valuation methods (EV/EBITDA and P/E) converge on a similar range.

Limits: (i) the June 2026 guidance cut shows FY26/FY27 earnings still depend heavily on how quickly pricing catches costs — a 5% miss on adj EBITA would push the low end of my range down materially; (ii) Eurotab synergies are unproven; (iii) meaningful downside if a second-order petrochemical shock compounds before pricing recovers.

Overall score rationale

This is a fair-to-cheap, quality-adequate, cyclically-recovering private-label manufacturer. It scores well on valuation discipline (low forward EV/EBITDA vs peers), reasonably on downside protection (defensive category, normalised balance sheet, growing PL demand). It scores poorly on the AI-receiver test — this is a chemicals/packaging manufacturer with essentially zero AI leverage, no AI-driven revenue line, no plausible AI-augmented margin expansion story. Operating leverage is only moderate. Given the investor's ~35% weight on AI beneficiary status, this cannot rank as a top-band buy for this strategy even at an attractive valuation.